NCT07018037 Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma
| NCT ID | NCT07018037 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Regina Elena Cancer Institute |
| Condition | Renal Cell Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-01-29 |
| Primary Completion | 2026-01-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-01-29 with a primary completion date of 2026-01-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.
Eligibility Criteria
Inclusion Criteria: * Patients over 18 years of age; * Histological diagnosis of clear cell renal cell carcinoma; * Evidence of advanced or metastatic disease; * Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI); * Patients able to comply with the study procedures. * Patients who give written informed consent personally or through a witness (study participation and data processing), before any study-specific procedure is started. Exclusion Criteria: * Previous neoplasms; * Previous antineoplastic treatments; * Previous steroid treatments; * Active viral infections (e.g., HCV, HIV, etc.); * Lack of autonomy in adhering to study procedures.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07018037 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Renal Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07018037 currently recruiting?
Yes, NCT07018037 is actively recruiting participants. Contact the research team at fabio.calabro@ifo.it for enrollment information.
Where is the NCT07018037 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT07018037 clinical trial?
NCT07018037 is sponsored by Regina Elena Cancer Institute. The trial plans to enroll 20 participants.